A range of blockbuster weight-loss and diabetes drugs could help shift the trajectory of the global obesity epidemic, which affects over one billion people worldwide, the World Health Organisation said on Monday.
A new generation of appetite-suppressing drugs called GLP-1 agonists, which includes blockbuster brands Ozempic and Mounjaro, has become massively popular in recent years.
On Monday, the United Nations health agency issued its first…
Read the full article here
